Vivani Medical (VANI) Corporate presentation summary

Market opportunity and challenges

• Obesity market is rapidly expanding, with GLP-1 products expected to reach $139B by 2030 and over 50 clinical-stage competitors, mostly injectables or orals.

• Poor medication adherence (<50%) and frequent discontinuation undermine efficacy and drive rapid weight rebound.

• Current therapies face tolerability, pricing, and access challenges, especially for hard-to-reach or convenience-seeking patients.

Technology and product differentiation

• NanoPortal platform enables ultra long-acting, subdermal drug implants for 6–12 month dosing intervals.

• Implants offer stable, tunable drug release, reducing side effects from dose fluctuations and ensuring guaranteed adherence.

• Infrequent, in-office administration by primary care professionals can reach underserved populations.

Clinical and preclinical results

• LIBERATE-1 first-in-human study met primary objectives, showing positive safety, tolerability, and device performance.

• Preclinical studies demonstrated sustained weight loss (up to -20% at 7 months) and 82% liver fat reduction in obese animal models.

• No serious adverse events or dose dumping observed in clinical trial; durable long-term delivery confirmed.